Regeneron Pharmaceuticals
Key Metrics
How this company measures up on the fundamentals that matter
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Valuation
Trading at $698 against a fair value of $1023, a 32% discount. Moderate competitive position. 30% profit margins. Passes all ethical screens. Ranks better than 95% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Market Data
Trading characteristics and market positioning
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Analyst Coverage
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-01 | RYAN ARTHUR F | Director | 100 | $70,524 | |
| 2026-04-01 | RYAN ARTHUR F | Director | 100 | $77,727 | |
| 2026-03-02 | RYAN ARTHUR F | Director | 100 | $78,550 | |
| 2026-02-19 | ZOGHBI HUDA Y | Director | 1,638 | $1,279,812 | |
| 2026-02-19 | ZOGHBI HUDA Y | Director | 1,638 | $617,018 | |
| 2026-02-09 | PITOFSKY JASON | Officer | 2,036 | $1,585,058 | |
| 2026-02-09 | RYAN ARTHUR F | Director | 100 | $77,853 | |
| 2026-02-09 | PITOFSKY JASON | Officer | 1,000 | $492,000 | |
| 2026-01-07 | BASSLER BONNIE L | Director | 1,500 | $1,200,000 | |
| 2026-01-07 | BASSLER BONNIE L | Director | 1,500 | $561,180 |
Political Trading Activity
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 1 May2026 | Ro Khanna | Democrat | sell | 1K–15K |
What If You'd Bought REGN?
| Period | Price Then | Price Return | Divs/Share | $1,000 Became | Total Return |
|---|---|---|---|---|---|
| 1 Month | $711.71 | -15.4% | $0.94 | $848 | -15.2% |
| 2 Months | $747.75 | -19.5% | $0.94 | $807 | -19.3% |
| 3 Months | $745.50 | -19.2% | $0.94 | $809 | -19.1% |
| 6 Months | $744.79 | -19.1% | $1.88 | $811 | -18.9% |
| 1 Year | $520.68 | +15.7% | $3.64 | $1,164 | +16.4% |
| 2 Years | $993.52 | -39.4% | $5.40 | $612 | -38.8% |
| 3 Years | $740.40 | -18.7% | $5.40 | $821 | -17.9% |
| 5 Years | $521.24 | +15.6% | $5.40 | $1,166 | +16.6% |
Historical returns. Past performance does not guarantee future results. Prices from market close data.
Framework Review History
Timestamped framework reads — tracking how the analysis evolves over time
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Latest Analysis — REGN
Timestamped intelligence from our daily research pipeline
12 June 2026 • Alpha Insights Sector Research Top 50 Healthcare Stocks Ranked: Pharma, Biotech, and MedTech Scored for Quality and Ethics Healthcare has become the quiet defensive rotation of...
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15